Genetic factors in affective illness.
Research strategies for determining genetic vulnerability markers in affective illness are delineated. Using these strategies, recent developments in the biology of manic-depressive illness are discussed, including results from association and linkage studies, pharmacologic challenge protocols, and cerebrospinal fluid (CSF) data. Several lines of evidence suggest that one genetically determined vulnerability to affective disorder may be a cholinergic supersensitivity, possibly mediated through increased numbers of cholinergic receptors.
D000017:ABO Blood-Group System; D001792:Blood Platelets; D002799:Cholinergic Fibers / Q000502:physiology; D004200:Diseases in Twins; D005260:Female; D008040:Genetic Linkage; D005819:Genetic Markers; D006680:HLA Antigens / Q000032:analysis; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007099:Imipramine / Q000378:metabolism; D019964:Mood Disorders / Q000134:cerebrospinal fluid / Q000235:genetics* / Q000503:physiopathology; D011247:Pregnancy; D012895:Sleep, REM; D014430:Twins, Monozygotic; D014439:Tyramine / Q000652:urine; D014960:X Chromosome; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid
D000017:ABO Blood-Group System; D005819:Genetic Markers; D006680:HLA Antigens; D006897:Hydroxyindoleacetic Acid; D005680:gamma-Aminobutyric Acid; D007099:Imipramine; D006719:Homovanillic Acid; D014439:Tyramine